ZiconotideSpecialtySafety Rating 4/10
Primary research areaSevere chronic pain refractory to other treatments
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range0.1-19.2 mcg/day intrathecal infusion
AdministrationIntrathecal infusion
Safety4/10 · FDA-approved (Prialt)
NCAA D1Not listed
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Ziconotide
Mechanism of action
N-type voltage-gated calcium channel blocker from cone snail venom omega-conotoxin MVIIA
Safety profile
Dizziness, nausea, confusion, severe neuropsychiatric effects · Carries an FDA black-box warning for severe psychiatric symptoms and cognitive impairment. Very narrow therapeutic window; intrathecal administration only. Approved for severe chronic pain but high-risk.
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Ziconotide below your target.
Related pages